Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PASTOR: Vistusertib + Palbociclib + Fulvestrant in ER+ Breast Cancer
NCT02599714Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2015
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of vistusertib in breast cancer, sponsored by AstraZeneca. Primary endpoint: Number of adverse events experienced by patients at 16 months. Started Dec 2015; status: completed.
02
Drugs
vistusertib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02599714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599714.